title: Late radiation effects to the rectum and bladder in gynecologic cancer patients: the comparison of LENT/SOMA and RTOG/EORTC late-effects scoring systems.
abstract: OBJECTIVE
  To test the correlation of LENT/SOMA and RTOG/EORTC late-effect scales for rectum and bladder, 116 cases with gynecologic malignancies that were treated with radiotherapy were assessed with both scales.
  
  
  METHODS
  All cases had been treated at least 6 months before the date of assessment with external beam radiotherapy (50--54 Gy to midline) and 1--2 fractions of HDR brachytherapy (2 x 8.5 Gy to point-A for 32 inoperable cases; 1 x 9.25 Gy to 5--9 mm from the ovoid surface for 84 postoperative cases). The patients were questioned with both scales, and the correlation between the two scales was analyzed by Spearman's rho (rank correlation) test.
  
  
  RESULTS
  There were 64 cases with uterine cervix carcinoma and 52 cases with endometrium carcinoma, The overall (external + brachy) doses to ICRU points were 57.8 +/- 3.8 Gy for rectum and 59.3 +/- 4.9 Gy for bladder. The statistical analysis of LENT/SOMA and RTOG/EORTC scales revealed a very good correlation for rectum (r = 0.81; p < 0.01) and a good correlation for bladder (r = 0.72; p < 0.01).
  
  
  CONCLUSIONS
  The LENT/SOMA system is a further step on the reporting of late radiation effects. Some modifications will improve its precision, and multicentric randomized studies are needed to test its validity.
authors.affiliation: Department of Radiation Oncology, Ege University Faculty of Medicine, Izmir, Turkey. yanacak@hotmail.com
authors.forename: Y
authors.initials: Y
authors.lastname: Anacak
authors.forename: D
authors.initials: D
authors.lastname: Yalman
authors.forename: Z
authors.initials: Z
authors.lastname: Ozsaran
authors.forename: A
authors.initials: A
authors.lastname: Haydaroğlu
mesh_terms: D000328:Adult; D000368:Aged; D001918:Brachytherapy / Q000009:adverse effects; D002277:Carcinoma / Q000150:complications / Q000532:radiotherapy* / Q000601:surgery; D003037:Cobalt Radioisotopes / Q000627:therapeutic use; D003131:Combined Modality Therapy; D016889:Endometrial Neoplasms / Q000150:complications / Q000532:radiotherapy* / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D010052:Ovariectomy; D010298:Parity; D011183:Postoperative Complications / Q000209:etiology; D011832:Radiation Injuries / Q000145:classification* / Q000209:etiology; D011867:Radioisotope Teletherapy / Q000009:adverse effects; D011878:Radiotherapy / Q000009:adverse effects*; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D012007:Rectum / Q000528:radiation effects*; D012720:Severity of Illness Index; D013997:Time Factors; D001743:Urinary Bladder / Q000528:radiation effects*; D002583:Uterine Cervical Neoplasms / Q000150:complications / Q000532:radiotherapy* / Q000601:surgery
chemical_list: D003037:Cobalt Radioisotopes